Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Receivables (2022 - 2025)

Marker Therapeutics (MRKR) has disclosed Receivables for 4 consecutive years, with $210000.0 as the latest value for Q3 2025.

  • Quarterly Receivables fell 34.38% to $210000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $210000.0 through Sep 2025, down 34.38% year-over-year, with the annual reading at $9.5 million for FY2024, 1261.16% up from the prior year.
  • Receivables for Q3 2025 was $210000.0 at Marker Therapeutics, down from $1.7 million in the prior quarter.
  • The five-year high for Receivables was $9.5 million in Q4 2024, with the low at $210000.0 in Q3 2025.
  • Average Receivables over 4 years is $2.8 million, with a median of $2.1 million recorded in 2024.
  • The sharpest move saw Receivables crashed 86.67% in 2024, then skyrocketed 1089.69% in 2025.
  • Over 4 years, Receivables stood at $3.7 million in 2022, then crashed by 58.49% to $1.5 million in 2023, then skyrocketed by 523.64% to $9.5 million in 2024, then tumbled by 97.8% to $210000.0 in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $210000.0, $1.7 million, and $4.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.